文献速递神经肿瘤

高级别胶质瘤出血相关不良结局的临床与分子决定因素

Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma.
PubMed 文献 · J Neurooncol · 2024-01-29

这项回顾性研究分析了2017年7月1日至2022年6月30日期间在奥斯汀两家学术医学中心就诊的75例病理确诊高级别胶质瘤患者,比较不同抗凝方案或未抗凝队列的临床与治疗相关因素。结果显示利伐沙班组出血相关不良事件比例高于阿哌沙班或依诺肝素组,且星形细胞瘤IDH突变4级与更多出血事件相关,但研究样本量小,需更大规模研究进一步评估。

要点

  • 利伐沙班组出血相关不良事件3/7(43%),高于阿哌沙班组0/12(0%)和依诺肝素组0/5(0%),p=0.022。
  • 星形细胞瘤IDH突变4级与更多出血相关事件相关,校正其他因素后OR为49.4(95%CI 2.8,2084.7;p=0.013)。
  • 抗凝与从未抗凝患者的人口学和临床特征无差异;研究样本量小,需更大规模研究进一步评估。

核心结论

  • 在高别胶质瘤患者中,利伐沙班的使用与较阿哌沙班和依诺肝素更多的出血相关事件相关。
  • 星形细胞瘤IDH突变4级的诊断与更多出血事件相关,但研究样本量小,需更大规模研究进一步评估。

研究设计与样本

  • 回顾性研究,纳入2017年7月1日至2022年6月30日期间在奥斯汀两家学术医学中心就诊的75例连续病理确诊高级别胶质瘤患者。
  • 比较接受不同形式抗凝或未抗凝队列的临床与治疗相关因素。

主要发现

  • 利伐沙班组出血相关不良事件为3/7(43%),阿哌沙班组为0/12(0%),依诺肝素组为0/5(0%),p=0.022。
  • 抗凝患者与从未抗凝患者在研究的人口学和临床特征方面无差异。
  • 逻辑回归分析显示,星形细胞瘤IDH突变4级与更多出血相关事件显著相关,校正其他相关因素后,与参考组GBM相比OR为49.4(95%CI 2.8,2084.7;p=0.013)。

局限性

  • 原文指出这是一项小型研究,需要更大规模的研究来进一步评估这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cancer is an independent risk factor for the development of venous thromboembolism (VTE). However, patients with high-grade glioma (HGG) including glioblastoma (GBM) are at a particularly high risk of VTE with an incidence up to 20-30% per year. Patients are often placed on anticoagulation if they are found to have VTE. However, patients with primary brain tumors such as HGG are at increased risk for intracerebral hemorrhage (ICH) even without the administration of anticoagulation. The combination of risk factors for ICH with anticoagulation and HGG complicates decision-making. Currently it is not known which of the direct oral anticoagulants (DOACs) are safest for patients with HGG in terms of adverse bleeding-related outcomes such as ICH. Furthermore, a deeper understanding of the clinical and molecular determinants of bleeding-related adverse outcomes in HGG is not fully characterized. METHODS: In this retrospective study, we identified and gathered data on 75 consecutive patients with pathology-confirmed HGG with hospital encounters at two academic medical center hospitals in Austin between July 1, 2017 and June 30, 2022. We compared clinical and treatment-related factors among cohorts who had received various forms of anticoagulation or no anticoagulation. RESULTS: Patients who were on rivaroxaban (3/7 (43%)) had a statistically significant association with more bleeding-related adverse events compared to those on apixaban (0/12 (0%)) or enoxaparin (0/5 (0%), p = 0.022) even though the groups were similar in characteristics including total time on the respective anticoagulation. Patients on anticoagulation vs those never on anticoagulation did not differ in terms of their studied demographic and clinical characteristics. Intriguingly, logistic regression analysis revealed that patients Astrocytoma, isocitrate dehydrogenase (IDH) mutant, grade 4 had a significant association with more adverse bleeding-related events even when controlling for other relevant factors (Odds Ratio compared to reference GBM: 49.4, 95% CI: 2.8, 2084.7; p = 0.013). CONCLUSION: In this study we found that the use of rivaroxaban was associated with more bleeding-related events compared to apixaban and enoxaparin in patients with high-grade glioma. In this study we also found that the diagnosis of astrocytoma, IDH mutant, grade 4 was associated with more bleeding events. However, this is based on a small study and there is a need for larger studies to further evaluate these results.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dasgupta P, Rousseau JF. Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma. J Neurooncol. 2024. PMID: 38286976. doi:10.1007/s11060-024-04574-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。